PTO/SB/26 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE sons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING

Docket Number (Optional)

(Mary Jo Nispel)

	REJECTION OVER A "PRIOR" PATENT	HYZ-027CIP2 (47508-580US4)
	In re Application of: Ekambar R. Kandimalla et al.	
	Application No.: 10/054,429	
	Filed: January 22, 2002	
	For: COOPERATIVE OLIGONUCLEOTIDES	
	The owner*, Idera Pharmaceuticals, Inc. , of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of prior patent No. 6,372,427  as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:  expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.  Check either box 1 or 2 below, if appropriate.  1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.  I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements w	
	2. X The undersigned is an attorney or agent of record. Reg. No4	6,967
	Signature Signature	Nov. 10, 2005
	Signature	Date
11/15/2005 AVELE	James T. Olesen, Pr CH1 00000037 080219 10054429 Typed or printed name	
		(617) 526-6000
01 FC:1814	130.00 DA	Telephone Number
	X Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
	*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	
	I hereby certify that this correspondence is being deposited with the U.S. Postal Service will an envelope addressed to: Commissioner for Patents, P.O. Box 1450 / Aexandria, VA 223	th sufficient postage as First Class Mail, in

Dated: 11-10-2005